Carvykti Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limitations of conventional myeloma therapies, early success of autologous cell therapies, unmet need in relapsed myeloma, advancements in gene modification techniques, expansion of oncology research funding.

The growth in the forecast period can be attributed to increasing multiple myeloma prevalence, broader regulatory approvals, scaling of cell therapy manufacturing, growing physician familiarity with car t protocols, expansion of specialized oncology centers. Major trends in the forecast period include expansion of car t cell therapies in hematologic cancers, rising adoption of personalized cancer treatments, growing focus on bcma targeted therapies, increasing investment in cell therapy manufacturing, centralization of advanced oncology treatment centers.

The growing prevalence of cancer is expected to drive the growth of the carvykti market in the coming years. Cancer encompasses a group of diseases characterized by uncontrolled growth and spread of abnormal cells, which can be fatal if untreated. The rising incidence of cancer is driven by factors such as an aging population, lifestyle choices, environmental exposures, and improved detection methods. Carvykti, a CAR T-cell therapy, addresses this growing prevalence by providing a targeted treatment for relapsed or refractory multiple myeloma, improving outcomes for patients with limited therapeutic options. For example, in May 2024, the National Cancer Institute, a US-based National Institute of Health, reported that as of January 2022, the United States had an estimated 18.1 million cancer survivors, a figure projected to increase to 22.5 million by 2032. Therefore, the growing prevalence of cancer is boosting the growth of the carvykti market.

A key trend in the carvykti market is the focus on developing innovative products such as autologous CAR-T therapies, designed to achieve durable, one-time remissions and enable earlier-line use in hematologic malignancies. Autologous CAR-T therapy involves engineering a patient’s own T cells to express a chimeric antigen receptor targeting a disease-specific antigen, providing a personalized treatment approach. For instance, in April 2024, Johnson & Johnson (Janssen), a US-based multinational pharmaceutical and biotechnology company, received expanded approval from the United States Food and Drug Administration for CARVYKTI (ciltacabtagene autoleucel) to treat adult patients with relapsed or refractory multiple myeloma after at least one prior line of therapy. This approval broadens the eligible patient population, allows earlier-line treatment, and leverages CARVYKTI’s dual single-domain antibody CAR design to enhance target avidity and T-cell activation. As a one-time infusion therapy with demonstrated Phase 3 benefits versus standard regimens, CARVYKTI strengthens the clinical and commercial case for CAR-T adoption in multiple myeloma.

In April 2023, Johnson & Johnson Services Inc., a US-based healthcare company, and Legend Biotech, a US-based biotechnology firm, partnered with Novartis to address supply constraints for CARVYKTI (cilta-cel), used in treating multiple myeloma. This collaboration aims to overcome challenges in meeting demand, particularly due to a global shortage of viral vectors essential for cell and gene therapies. Novartis AG, a Switzerland-based pharmaceutical company, develops innovative medications including carvykti.

Major companies operating in the carvykti market are Johnson & Johnson Services Inc., Legend Biotech, Novartis AG.

North America was the largest region in the carvykti market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carvykti market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the carvykti market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the carvykti market by increasing costs for imported viral vectors, cell processing equipment, and cold chain logistics. These effects are most visible in hospital pharmacies and oncology treatment centers. Regions dependent on cross-border manufacturing face higher operational expenses. However, tariffs are encouraging local cell therapy production investments. This supports long-term manufacturing resilience and supply stability.

The carvykti market research report is one of a series of new reports that provides carvykti market statistics, including carvykti industry global market size, regional shares, competitors with a carvykti market share, detailed carvykti market segments, market trends and opportunities, and any further data you may need to thrive in the carvykti industry. This carvykti market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Carvykti (ciltacabtagene autoleucel) is a CAR-T cell therapy for adults with relapsed or refractory multiple myeloma who have undergone at least four prior lines of treatment. It works by genetically modifying a patient’s T cells to recognize and eliminate cancerous plasma cells that express the BCMA (B-cell maturation antigen) protein.

The primary type of carvykti is cell therapy, specifically autologous T-cell therapy. This approach uses a patient’s own T cells, which are collected from the blood and modified in a laboratory to better identify and attack cancer cells, such as those in multiple myeloma. It is indicated for multiple myeloma, including relapsed or refractory cases, primarily in adult patients. Carvykti is distributed through hospital pharmacies, stem cell banks, and outpatient clinics.

The carvykti market consists of sales of kymriah, yescarta, breyanzi, pomalyst. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.